google-site-verification=iUxCUgpoCQNGCS2CQuHi1L8aGqyfkykwcZUHtbSwrts
top of page
< Back

Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients

Molecular Systems Biology

October 25, 2021

Zeybel, Mujdat

Summary

Nonalcoholic fatty liver disease (NAFLD) refers to excess fat accumulation in the liver. In animal experiments and human kinetic study, we found that administration of combined metabolic activators (CMAs) [l-carnitine tartrate, nicotinamide riboside, L-serine, and N-acetyl-l-cysteine] promotes the oxidation of fat, attenuates the resulting oxidative stress, activates mitochondria, and eventually removes excess fat from the liver. Here, we tested the safety and efficacy of CMA in NAFLD patients in a placebo-controlled 10-week study. We found that CMA significantly decreased hepatic steatosis and levels of aspartate aminotransferase, alanine aminotransferase, uric acid, and creatinine, whereas found no differences on these variables in the placebo group after adjustment for weight loss. By integrating clinical data with plasma metabolomics and inflammatory proteomics as well as oral and gut metagenomic data, we revealed the underlying molecular mechanisms associated with the reduced hepatic fat and inflammation in NAFLD patients and identified the key players involved in the host–microbiome interactions. In conclusion, we showed that CMA can be used to develop a pharmacological treatment strategy in NAFLD patients.

Follow Us!

  • Instagram
  • Facebook
  • Twitter
Screen Shot 2022-12-28 at 9.59.55 AM.png
Photo of the site's author, Shelly Albaum - 148x200

I am Shelly Albaum, and this is my personal website and blog. All the opinions presented here are my own. Nobody writes here but me. You can read more about me here. Cookies are not required to use this website. Read more about that here. 

​

Original work © 2022 by Right of Assembly

No claim to research or any work of others

IMPORTANT DISCLOSURES

1. Health Supplements Are Not Medicines. Health Supplements that raise NAD levels, like nicotinamide riboside or other NAD precursors, are not intended to diagnose, treat, cure, or prevent any disease.

​

2. No Medical Advice. I am a lawyer and a journalist, not a doctor, and I offer no medical advice. But I do follow the science, and I can bring to your attention some interesting studies. You can read more about me here. And check with your physician -- your physician can look at this research, too.

​

3. Commercial Affiliations. I am a ChromaDex shareholder, and a marketing affiliate for Amazon and Rakuten. As a result, I will sometimes mention or recommend products that I endorse, like Tru Niagen, which I take every day. I may earn a small commission from qualifying purchases if you were referred directly from this site and completed a purchase. [Thank you!] You can read more about our advertising, privacy, and data collection policies here

bottom of page